Xiaoyu Hu - Publications

Affiliations: 
University of Rochester, Rochester, NY 

14 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Hu X, Zhao M, Bai M, Xue Z, Wang F, Zhu Z, Yu J, Yue J. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation. Cancer Letters. 216676. PMID 38278469 DOI: 10.1016/j.canlet.2024.216676  0.316
2023 Liu C, Li X, Huang Q, Zhang M, Lei T, Wang F, Zou W, Huang R, Hu X, Wang C, Zhang X, Sun B, Xing L, Yue J, Yu J. Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer. Signal Transduction and Targeted Therapy. 8: 44. PMID 36710358 DOI: 10.1038/s41392-022-01264-9  0.319
2022 Shen X, Zhang B, Hu X, Li J, Wu M, Yan C, Yang Y, Li Y. and inhibited oral squamous cell carcinomas by regulating genome stability. Bioengineered. 13: 14094-14106. PMID 35734856 DOI: 10.1080/21655979.2022.2078556  0.326
2022 Hu X, Li L, Eid JE, Liu C, Yu J, Yue J, Trent JC. IDH1 Mutation Induces HIF-1 and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells. Disease Markers. 2022: 7729968. PMID 35198082 DOI: 10.1155/2022/7729968  0.319
2020 Wang L, Gao Y, Zhang G, Li D, Wang Z, Zhang J, Hermida LC, He L, Wang Z, Si J, Geng S, Ai R, Ning F, Cheng C, Deng H, ... ... Hu X, et al. Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Science Translational Medicine. 12. PMID 32908002 DOI: 10.1126/Scitranslmed.Aax2282  0.306
2019 Xiao Z, Chang L, Kim J, Zhang P, Hang Q, Yap S, Guo Y, Zhou Z, Zeng L, Hu X, Siverly A, Sun Y, Ma L. USP37 is a SNAI1 deubiquitinase. American Journal of Cancer Research. 9: 2749-2759. PMID 31911859  0.382
2019 Li L, Hu X, Trent JC. Depletion of mutant IDH1 impairs chondrosarcoma growth by downregulating integrins. Journal of Clinical Oncology. 37: 11031-11031. DOI: 10.1200/JCO.2019.37.15_SUPPL.11031  0.315
2018 Chu Y, Wang Y, Peng W, Xu L, Liu M, Li J, Hu X, Li Y, Zuo J, Ye Y. STAT3 activation by IL-6 from adipose-derived stem cells promotes endometrial carcinoma proliferation and metastasis. Biochemical and Biophysical Research Communications. PMID 29684351 DOI: 10.1016/j.bbrc.2018.04.121  0.328
2017 Zhou Z, Zhang P, Hu X, Kim J, Yao F, Xiao Z, Zeng L, Chang L, Sun Y, Ma L. USP51 promotes deubiquitination and stabilization of ZEB1. American Journal of Cancer Research. 7: 2020-2031. PMID 29119051  0.358
2017 Zhang Y, Xu W, Guo H, Zhang Y, He Y, Lee SH, Song X, Li X, Guo Y, Zhao Y, Ding C, Ning F, Ma Y, Lei QY, Hu X, et al. NOTCH1 Signaling Regulates Self-renewal and Platinum Chemoresistance of Cancer Stem-like Cells in Human Non-small Cell Lung Cancer. Cancer Research. PMID 28416482 DOI: 10.1158/0008-5472.CAN-16-1633  0.313
2015 Zeng M, Yang Z, Hu X, Liu Y, Yang X, Ran H, Li Y, Li X, Yu Q. Grb7 gene amplification and protein expression by FISH and IHC in ovarian cancer. International Journal of Clinical and Experimental Pathology. 8: 11296-304. PMID 26617853  0.358
2014 Hu X, Zhou Y, Dong K, Sun Z, Zhao D, Wang W, Yu G, Liu W, Xu G, Han Z, Feng X. Programming of the development of tumor-promoting neutrophils by mesenchymal stromal cells. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 33: 1802-14. PMID 24923759 DOI: 10.1159/000362959  0.311
2013 Hu X, Dutta P, Tsurumi A, Li J, Wang J, Land H, Li WX. Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 110: 10213-8. PMID 23733954 DOI: 10.1073/Pnas.1221243110  0.364
2013 Qian X, Gu L, Ning H, Zhang Y, Hsueh EC, Fu M, Hu X, Wei L, Hoft DF, Liu J. Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2. Journal of Immunology (Baltimore, Md. : 1950). 190: 5894-902. PMID 23645882 DOI: 10.4049/Jimmunol.1203141  0.322
Show low-probability matches.